Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas A Bell

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Cancer Letters|February 28, 2002
XRCC1 polymorphisms and head and neck cancerAndrew F Olshan, Mary A Watson, Mark C Weissler, et al.
Ecology and Evolution|July 27, 2012
Hybridization among Arctic white-headed gulls (Larus spp.) obscures the genetic legacy of the PleistoceneSarah A Sonsthagen, R Terry Chesser, Douglas A Bell, et al.
Current Opinion in Toxicology|September 19, 2017
Potential therapeutic targets in Nrf2-dependent protection against neonatal respiratory distress disease predicted by cDNA microarray analysis and bioinformatics toolsHye-Youn Cho, Xuting Wang, Jianying Li, et al.
Nucleic Acids Research|September 7, 2010
Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elementsOmari J Bandele, Xuting Wang, Michelle R Campbell, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2005
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotypeSu-Jun Lee, Douglas A Bell, Sherry J Coulter, et al.
Clinical Epigenetics|July 1, 2026
Impact of tobacco smoking on estimated telomere shortening and epigenetic age acceleration among human blood immune cell typesXuting Wang, Michelle R Campbell, Suzanne N Martos, et al.
Cancer Research|November 13, 2003
p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factorsJane C Schroeder, Kathleen Conway, Yu Li, et al.
Mutation Research|April 22, 2004
Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human bloodDelores J Grant, Ingrid J Hall, David A Eastmond, et al.
Oxidative Medicine and Cellular Longevity|June 15, 2013
Novel hematopoietic target genes in the NRF2-mediated transcriptional pathwayMichelle R Campbell, Mehmet Karaca, Kelly N Adamski, et al.
Free Radical Biology & Medicine|July 12, 2015
Beyond antioxidant genes in the ancient Nrf2 regulatory networkSarah E Lacher, Joslynn S Lee, Xuting Wang, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Cancer Letters|February 28, 2002
XRCC1 polymorphisms and head and neck cancerAndrew F Olshan, Mary A Watson, Mark C Weissler, et al.
Ecology and Evolution|July 27, 2012
Hybridization among Arctic white-headed gulls (Larus spp.) obscures the genetic legacy of the PleistoceneSarah A Sonsthagen, R Terry Chesser, Douglas A Bell, et al.
Current Opinion in Toxicology|September 19, 2017
Potential therapeutic targets in Nrf2-dependent protection against neonatal respiratory distress disease predicted by cDNA microarray analysis and bioinformatics toolsHye-Youn Cho, Xuting Wang, Jianying Li, et al.
Nucleic Acids Research|September 7, 2010
Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elementsOmari J Bandele, Xuting Wang, Michelle R Campbell, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2005
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotypeSu-Jun Lee, Douglas A Bell, Sherry J Coulter, et al.
Clinical Epigenetics|July 1, 2026
Impact of tobacco smoking on estimated telomere shortening and epigenetic age acceleration among human blood immune cell typesXuting Wang, Michelle R Campbell, Suzanne N Martos, et al.
Cancer Research|November 13, 2003
p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factorsJane C Schroeder, Kathleen Conway, Yu Li, et al.
Mutation Research|April 22, 2004
Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human bloodDelores J Grant, Ingrid J Hall, David A Eastmond, et al.
Oxidative Medicine and Cellular Longevity|June 15, 2013
Novel hematopoietic target genes in the NRF2-mediated transcriptional pathwayMichelle R Campbell, Mehmet Karaca, Kelly N Adamski, et al.
Free Radical Biology & Medicine|July 12, 2015
Beyond antioxidant genes in the ancient Nrf2 regulatory networkSarah E Lacher, Joslynn S Lee, Xuting Wang, et al.
Pageof 10